Other languages Aptose Biosciences Inc.

Equities

APS

CA03835T3091

Market Closed - Toronto S.E. Other stock markets 16:00:00 2024-05-03 EDT			5-day change	1st Jan Change
1.64 ^CAD	-0.61%		-3.53%	-51.04%

04-25	Certain Warrants of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI
04-25	Certain Common Shares of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26
Aptose Biosciences Up 3% After Hours as its 2023 Loss Widens on Higher R&D Spending	03-26
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26
Top Premarket Gainers	02-02
Wall Street Set to Open Marginally Lower Friday; December Inflation Data Lower Than Forecast	01-26
US Futures Nudge Lower in Friday's Premarket Ahead of Fed Inflation Data	01-26
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting	12-09
Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business Officer	11-30
Aptose Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Aptose Biosciences Third-Quarter Loss Widens on Higher R&D Spending	11-09
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting	11-02
RBC Capital on Aptose Biosciences' ESH Data Update	23-10-31
Aptose Biosciences Inc. Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib	23-10-30
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th	23-10-23
Vastzetting: Ethereum scheert hoge toppen - cryptonieuws	23-09-09
Staking: Ethereum raggiunge nuove vette - Resoconto Cripto	23-09-08
Aptose Biosciences Inc. Provides A Recent Update from an Ongoing Aptivate Phase 1/2 Clinical Trial with the Company's Lead Agent, Tuspetinib	23-08-24
Top Premarket Decliners	23-08-16
RBC Capital on Aptose Biosciences' APTIVATE Trial, Cuts Target to US$23	23-08-11
Aptose Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aptose Biosciences Inc.

Equities

APS

CA03835T3091

Other languages

Filters